Among patients with stage II or III colorectal cancer, more frequent follow-up testing with CT scans and CEA testing did not result in a significant reduction in 10-year overall mortality or colorectal cancer–specific mortality. This evidence concerns the gene CEACAM5 and colorectal cancer.